The United States Patent and Trademark Office (USPTO) has granted US patent number 8,343,485 to NeoStem's lead product candidate, AMR-001. The patent entitled “Compositions and methods of Vascular Injury Repair” is the third US granted patent for AMR-001, protecting further expansion of its CD34+ chemotactic stem cell product composition claim as well as method of sourcing and administration of cells claims.
Dr Andrew L Pecora, chief medical officer of NeoStem, said, “NeoStem’s intellectual property portfolio around its phase II stem cell compound continues to expand in critical ways. With the grants of its last three US patents, AMR-001 now enjoys greater protection in terms of its CD34 cell content and the indications for its use, which include treating any vascular injury caused by vascular insufficiency, covering CD34 stem cells sourced from bone marrow or peripheral blood and administered parenterally into an artery, vein or muscle.”
"This successful expansion of NeoStem's intellectual property improves our ability to protect our most mature clinical asset," said Dr Robin L Smith, chairman and CEO of NeoStem. "We believe the IP around AMR-001, our stem cell therapy, is strong and broad and we continue to pursue incremental protection with no fewer than 30 additional patents pending around the world."
NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that occurs in medicine.